May 26, 2017 09:33 AM EDTUpdated 10:27 AM
News Briefing

Venn and Uni­ver­si­ty of Utah part­ner on im­muno-on­col­o­gy mol­e­cule; Bio­gen los­ing an­oth­er ex­ec

Emma Yasinski

→ Venn Ther­a­peu­tics plans to ad­vance a small mol­e­cule de­signed by Haitao (Mark) Ji at the Uni­ver­si­ty of Utah. The mol­e­cule is a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times